cdmo.directory
← Compare landing

Lacamas Laboratories Inc. vs 重庆兴泰濠制药有限公司 (Sintaho)

Auto-generated comparison by BioBM Editorial AI. This page highlights available profile evidence side by side and avoids drawing conclusions from missing fields.

Markdown mirror: /api/markdown/compare/lacamaslabs/sintaho

CategoryLacamas Laboratories Inc.重庆兴泰濠制药有限公司 (Sintaho)
Listed sitecdmocdmo
SummaryLarge-scale contract manufacturer of pharmaceutical intermediates and fine chemicals with over 32,000 gallons of reactor capability, specializing in process development, scale-up, and hazardous chemistry handling.China-based API and CDMO/CMO supplier focused on cytotoxic and OEB5 high-potency APIs, peptides, and XDC compounds. Reports FDA on-site inspections in 2024 and 2025 and product registrations in more than 30 countries.
Services
  • Process Development
  • API Synthesis & Manufacturing
  • Small Molecule Development & Manufacturing
  • API Synthesis & Manufacturing
  • HPAPI Manufacturing (High-Potency)
  • Peptide Manufacturing
  • Small Molecule Development & Manufacturing
Modalities
  • Small Molecule
  • Small Molecule
  • Peptide
IndicationsData not yet provided.Data not yet provided.
Locations
  • Headquarters, Portland, Oregon, United States
  • Manufacturing Facility, Albany, Oregon, United States
  • Headquarters, Chongqing, Chongqing, China
CertificationsData not yet provided.
  • Internet Drug Information Service Qualification (Chongqing) · Identifier: （渝）-非经营性-2022-0020
ReviewsReview summary appears after site-level review signal gate opens.Review summary appears after site-level review signal gate opens.